GGrantIndex
Sort

21,453 grants matching tuberculosis

M.tuberculosis Rpfs: Modulators of Reactivation

$241,779
Joann M Tufariello · Albert Einstein College Of Medicine · R21 · FY2007 · AI

Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agents

$241,715
Max O'Donnell · Columbia University Health Sciences · R21 · FY2023 · AI

VU-Mozambique Collaborative Research Ethics Education Program

$241,698
D. Troy Moon · Vanderbilt University · R25 · FY2015 · TW

TB Alliance CETR Administrative Core

$241,677
Nader Fotouhi · Global Alliance For Tb Drug Development · U19 · FY2019 · AI

Structural Biology of Protein Complexes of Mtb

$241,546
David S Eisenberg · Texas A&M University · P01 · FY2013 · AI

Macaque T cell signatures of Mtb control

$241,509
Jyothi Rengarajan · Emory University · U19 · FY2019 · AI

BACTERIAL AND LIPOSOMAL ANTIGEN PROCESSING

$241,501
Case Western Reserve University · R01 · FY2000 · AI

GAIT complex formation and Mycobacterium tuberculosis

$241,500
Liem Duy Nguyen · Case Western Reserve University · R21 · FY2021 · AI

Multiplexed point-of-care molecular detection for multiple infections in co-endemic settings

$241,500
Robert M Greenberg · University Of Pennsylvania · R21 · FY2017 · AI

Impact of Pregnancy on Tuberculosis

$241,484
Jerrold J. Ellner · Boston Medical Center · R01 · FY2018 · AI

Vanderbilt Infection Pathogenesis and Epidemiology Research Training Program

$241,426
Spyros A Kalams · Vanderbilt University · T32 · FY2014 · AI

Regulation of antibiotic tolerance in Mycobacterium abscessus by proteolytic signaling

$241,375
Bennett Penn · University Of California At Davis · R21 · FY2024 · AI

Noncompetitive inhibition of CYP121 dimers from Mycobacterium tuberculosis

$241,375
David Fernando Estrada · State University Of New York At Buffalo · R21 · FY2024 · AI

PROGRESSIVE IMPAIRMENT OF LUNG IMMUNITY IN HIV INFECTION

$241,330
Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2000 · HL

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$241,329
Shabaana A. Khader · Washington University · R01 · FY2021 · AI

Tuberculosis Elimination and Laboratory Program Funding. The Rhode Island Tubercu

$241,295
Utpala Bandy · Rhode Island State Dept Of Health · U52 · FY2014 · PS

Mali International Center for Excellence in Research: Filariasis

$241,289
Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Analysis of Host-Pathogen Interactions

$241,185
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics

$241,150
Kyle H Rohde · University Of Central Florida · R21 · FY2021 · AI

Crystalline Endolysin Treatment for Tuberculosis in TB/HIV co-infected patients

$241,150
Bhami Shenoy · Procrysta Biologix, Inc. · R43 · FY2011 · AI

Long-term Effects of Early-Life Arsenic Exposure on Immunity

$241,096
Fenna Sille · Johns Hopkins University · R00 · FY2019 · ES

Mopati: A Pilot HIV Treatment Partner Intervention in Botswana

$241,074
Laura M Bogart · Rand Corporation · R34 · FY2021 · MH

Reduced Injectable, Short-course for (E)Xpert MDR-TB [RISE trial]

$241,000
Scott K Heysell · University Of Virginia · R34 · FY2014 · AI

A Novel Clock to Monitor M. tuberculosis in vivo

$241,000
David R Sherman · Seattle Biomedical Research Institute · R21 · FY2010 · HL

Novel strategies for treatment of Mycobacterium abscessus pulmonary disease

$240,878
Susan E Dorman · Medical University Of South Carolina · R34 · FY2025 · AI